The document discusses developing a viral removal device to prevent hepatitis C virus (HCV) recurrence after liver transplantation. It hypothesizes that eliminating circulating virus before transplant reperfusion would prevent recurrence, while reducing virus levels could delay or prevent recurrence if combined with other interventions. The proposed device would be implemented during the anhepatic phase of transplant when no liver is present to actively replicate virus. The document considers using antibodies, peptides, or hepatocytes to selectively bind and remove HCV from blood flowing through the device at rates of 1-2 liters per minute to cure HCV infection. Key challenges are determining the best method to bind virus and manufacturing complications.